Recent clinical studies demonstrated a significant association between the serum and CSF levels of CHI3L1 with disability accumulation, cognitive decline and disease progression in MS patients [88,89,90,91,92]. This evidence concerns the gene CHI3L1 and myeloid sarcoma.